Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | JUN | P05412 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.39 |
| ▸ | RELA | Q04206 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8574413 | 0.89 | MAPT (0.57) | RXFP1MAPTGPR35SLC13A3P2RX1 | |
| SCHEMBL30631299 | 0.88 | MAP4K4 (0.41) | RXFP1MAP4K4CA12CA1CA9 | |
| SCHEMBL28756123 | 0.88 | MAP4K4 (0.41) | RXFP1MAP4K4CA12CA1CA9 | |
| SCHEMBL10305747 | 0.86 | MAP4K4 (0.46) | ALDH1A1MAP4K4CA12CA1CA2 | |
| SCHEMBL13996788 | 0.84 | MAPT (0.51) | RXFP1MAPTGPR35SLC13A3P2RX1 | |
| SCHEMBL1358061 | 0.82 | ACP1 (0.53) | RXFP1MAPTGPR35SLC13A3TRPA1 | |
| SCHEMBL8572362 | 0.82 | SLC13A3 (0.63) | RXFP1MAPTGPR35SLC13A3P2RX1 | |
| SCHEMBL27118826 | 0.82 | RXFP1 (0.46) | RXFP1MAPTGPR35SLC13A3TRPA1 | |
| SCHEMBL6645666 | 0.81 | RXFP1 (0.47) | RXFP1MAPTGPR35SLC13A3P2RX1 | |
| SCHEMBL12097686 | 0.81 | P2RY14 (0.48) | RXFP1MAPTGPR35SLC13A3P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-1667966-B1 | N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7863333-B2 | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1617803-B1 | MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-1667966-A4 | N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7468440-B2 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1660445-A4 | LACTAMS OF ALKYLATED ACYCLIC DIAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20080113976-A1 | N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7317019-B2 | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1617803-A4 | MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1667966-A1 | N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1660445-A1 | LACTAMS OF ALKYLATED ACYCLIC DIAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1617803-A2 | MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050065147-A1 | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-24 | — | — | US | disclosed |
| WO-2005021498-A1 | LACTAMS OF ALKYLATED ACYCLIC DIAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021499-A1 | N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050043392-A1 | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-24 | — | — | US | disclosed |
| US-20040235835-A1 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| WO-2004098512-A2 | MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235835-A1 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | RXFP1 127/4885MAPT 4455/4885GPR35 262/4885 |
| US-20080113976-A1 | N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCR1, CCR2 | RXFP1 158/4885MAPT 4701/4885GPR35 63/4885 |
| US-20050065147-A1 | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | RXFP1 158/4885MAPT 4701/4885GPR35 63/4885 |
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | RXFP1 147/4885MAPT 2899/4885GPR35 1636/4885 |
| US-20050043392-A1 | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | RXFP1 91/4885MAPT 4432/4885GPR35 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.